拓扑特肯体内外抗肿瘤作用的研究  

Antitumor Action in Vitro and in Vivo of Topotecan

作　　者：刘红[1] 张肇铭[1] 

机构地区：[1]山西大学生命科学系,山西 太原 030006

出　　处：《山西大学学报（自然科学版）》2000年第4期350-353,共4页Journal of Shanxi University(Natural Science Edition)

摘　　要：测定了拓扑特肯对 5种体外培养人肿瘤细胞株的生长抑制作用及对小鼠移植性肿瘤的抑制作用。结果显示拓扑特肯对各体外肿瘤细胞都有明显的细胞毒作用 ,除了对人胃癌 BGC- 80 3的 IC5 0 为 3.87μg/ m L 外 ,对其它瘤株的 IC5 0 均小于 0 .1μg/ m L。在 1.0 m g/ kg、2 .0 m g/ kg剂量下 ,拓扑特肯对小鼠肉瘤 S1 80 的抑制率分别为 32 .0 %、33.8% ;对小鼠肝癌 H2 2 的抑制率分别为 31.4% ,42 .1% ,在 2 .0 mg/ kg剂量下对小鼠 L ewis肺癌的抑制率为 6 0 .8% ,与对照组比较都具有极显著差异 ( P<0 .0 1)。The anti-tumor activity of Topotecan to five human tumor cells in vitro and mice transplanted tumor cells in vivo were studied.The results showed that Topotecan had obviously cytotoxic effect on tumor cells in vitro,and the IC 50 were all less than 0.1μg/mL except for 3.87μg/mL to BGC-803.At doses of 1.0mg/kg、2.0mg/kg,the inhibiting rate to mice sarcoma S 180 were 32.0%,33.8% respectively,and the inhibiting rate to mice H 22 liver neoplasm were 31.4%、42.1% respectively.At the dose of 2.0mg/kg,the inhibiting rate to mice Lewis lung carcinoma was 60.8%.It is showed that the changes had significant difference as compared with the control group.

关 键 词：拓扑特肯 人肿瘤细胞 抑制作用 

分 类 号：R979.1[医药卫生—药品]